Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 44 results for "Zohydro"

hydrocodone (Zohydro ER)

What is ? Hydrocodone is an opioid narcotic pain-reliever similar to oxycodone , morphine, methadone , fentanyl, and other opioids. Is hydrocodone (Zohydro ER) available as a generic drug? No Do I need a prescription for hydrocodone (Zohydro ... MedicineNet.com, 2 weeks ago
Oxycodone vs. Hydrocodone MedicineNet.com, 2 weeks ago

Najib Babul - Discusses Current Challenges with Chronic Pain Management

/ Chronic pain is a major public health problem that afflicts a significant number of patients, resulting in personal suffering, reduced productivity, and increased health care costs. A report from the National Academy of Medicine states that ...
 4 Traders1 week ago Najib Babul Discusses Current Challenges with Chronic Pain Management  SSUChronicle.com1 week ago
[x]  
Yahoo! Finance

The FDA's Historic Caution On Abuse Deterrent Labeling

Before the market open on Friday, IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI ) reported its NDA submission for its abuse-deterrent Rexista (oxycodone hydrochloride) extended release tablets designed in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg ...
 Benzinga.com1 week ago
[x]  

PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 21, 2016, the Board of Directors (the Board) of Pernix Therapeutics ...
 4 Traders1 week ago

Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

Net Revenue Increased 13% Sequentially Over Second Quarter 2016 Prescription Volumes Grew Sequentially and Year-Over-Year for All Three Core Brands, Treximet ® , Zohydro ER ® with BeadTek and Silenor ® MORRISTOWN, N.J., Nov. 10, 2016 ...
 BioSpace3 weeks ago Pernix Reports Third Quarter 2016 Financial Results And Provides Business Update  BioSpace3 weeks ago
[x]  

Pernix Therapeutics' (PTX) CEO John Sedor on Q3 2016 Results - Earnings Call Transcript

Pernix Therapeutics Holdings, Inc. (NYSEMKT: PTX ) Q3 2016 Results Earnings Conference Call November 10, 2016 04:30 PM ET Executives John Sedor - Chairman and CEO Graham Miao - President and CFO George Jones - VP, Sales and ...
 Seeking Alpha3 weeks ago Zogenix's (ZGNX) CEO Stephen Farr on Q3 2016 Results - Earnings Call Transcript  Seeking Alpha3 weeks ago Edited Transcript of PTX earnings conference call or presentation 11-Aug-16 8:30pm GMT  Yahoo! Finance1 month ago

Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results

EMERYVILLE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a corporate update and announced ...
 4 Traders3 weeks ago
[x]  

Zogenix beats by $0.27, beats on revenue

Zogenix (NASDAQ:ZGNX): Q3 EPS of -$0.69 beats by $0.27. Revenue of $6.6M (-27.6% Y/Y) beats by $3.5M. Now read: Cutera beats by $0.08, beats on revenue » From other sites Stocks derailed by high-flyers; worst day since 2011 for Nasdaq at ...
 Seeking Alpha3 weeks ago

UPDATED: Daiichi adds abuse-deterrent opioid to pain portfolio

Japan's Daiichi Sankyo has made developing a portfolio of pain-management products a key R&D focusand just added two new drugs to the mix. The company has licensed U.S. rights to Inspirion Delivery Sciences' already-approved MorphaBond (morphine ...
 FiercePharma1 month ago
Analyst Ratings.com

Oppenheimer Thinks Zogenix's Stock is Going to Recover

In a report released today, Rohit Vanjani from Oppenheimer assigned a Buy rating to Zogenix (NASDAQ: ZGNX ), with a price target of $16 . The company's shares opened today at $8.85, close to its 52-week low of $7.33. According to TipRanks.com , ...
 Analyst Ratings.com1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less